Survival Benefit of Chemotherapy According to 21-Gene Recurrence Score in Young Women with Breast Cancer-Reference-Cited by-同舟云学术

Survival Benefit of Chemotherapy According to 21-Gene Recurrence Score in Young Women with Breast Cancer

Published:2023-01-08 Issue:4 Volume:30 Page:2130-2139
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Nash A. L.,Ren Y.,Plichta J. K.,Rosenberger L. H.,van den Bruele A. M. B.,DiNome M. L.,Westbrook K.,Hwang E. Shelley^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1245/s10434-022-12699-3.pdf

Reference23 articles.

1. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years. Lancet. 2000;355(9217):1822. https://doi.org/10.1016/s0140-6736(00)02277-7.

2. Mariotto A, Feuer EJ, Harlan LC, Wun L-M, Johnson KA, Abrams J. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975–1999. J Natl Cancer Inst. 2002;94(21):1626–34.

3. Group EBCTC. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717. https://doi.org/10.1016/s0140-6736(05)66544-0.

4. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997;89(22):1673–82.

5. Fisher B, Redmond C. Systemic therapy in node-negative patients: updated findings from NSABP clinical trials. J Natl Cancer Inst Monogr. 1992;11:105–16.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant Chemotherapy in Premenopausal Patients With Hormone-Positive Breast Cancer With a Recurrence Score of 16-25: A Retrospective Analysis Using the National Cancer Database;JCO Precision Oncology;2024-03